MK0777
Phase 2Small molecule
Merck & Co.MK0777 is one of 61 small molecule programs targeting Generalized Anxiety Disorder. It is currently in Phase 2.
2
Indications
4
Total Trials
0
Active Trials
60
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
82 competitors in Generalized Anxiety Disorder
#DrugCompanyPhaseTrials
1Brintellix
TakedaPhase 3
Viibryd
AbbViePhase 3
Seroquel
EEngelhard Arzneimittel GmbH & Co.KG
Phase 3
PD 0360324
PfizerPhase 3
Risperdal
WWim Janssens
Phase 3
Effexor
WWyeth-Lederle Vaccines
Phase 3
Quetiapine XR
AstraZenecaPhase 3
Lu AF95245
LundbeckPhase 3
Vraylar
AbbViePhase 2
Venlafaxine XR
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Generalized Anxiety Disorder2 trials
Unspecified1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for MK0777. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company